Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$89.43

4.68 (5.52%)

, AMGN

Amgen

$184.88

-0.72 (-0.39%)

12:19
09/28/17
09/28
12:19
09/28/17
12:19

On The Fly: Top stock stories at midday

Stocks began the session in negative territory but saw their lows a short time after the open. The averages have drifted higher to turn mixed near noon, with the Dow managing to cross into the green, the S&P flat and Nasdaq mildly lower. The day's economic data had little effect on the market as the focus at the moment continues to be the Trump administration tax reform plan, debate about its merits and its chances to go from an outline into law. ECONOMIC EVENTS: In the U.S., Q2 GDP growth was revised up to a 3.1% rate from the prior 3.0% estimate, as expected for the third look at the data. The advance goods trade deficit narrowed slightly to $62.9B in August from a revised July estimate of $63.9B. Initial jobless claims rose 12,000 to 272,000 in the fourth week of September. COMPANY NEWS: Chevron (CVX) announced that Michael Wirth has been selected as its next chairman of the board and CEO, effective this coming February. Wirth, currently vice chairman and executive vice president of Midstream and Development, succeeds John Watson, who has been chairman and CEO for the last eight years as part of his 37 year tenure with the energy giant... AbbVie (ABBV) announced a global resolution of all intellectual property-related litigation over Amgen's (AMGN) proposed biosimilar version of Humira, the world's best selling drug... Shares of BlackBerry (BBRY) have jumped 14% after the company reported an unexpected profit, on an adjusted basis, for the last three months and said it is on track to achieve profitability for the full year... MAJOR MOVERS: Among the notable gainers was Spectrum Pharmaceuticals (SPPI), which jumped over 18% after announcing efficacy data for lung cancer drug poziotinib that analysts called "encouraging." Also higher was Abbott (ABT), which rose 3% after the FDA approved its no-stick FreeStyle Libre Flash Glucose Monitoring System for adults with diabetes. Dexcom (DXCM) was among the noteworthy losers, dropping 33% after competitor Abbott's glucose monitoring system gained FDA approval. Several analysts commented on the news this morning, with JPMorgan, Raymond James and Northland downgrading Dexcom given not only the approval of the system but the nature of the label that the FDA granted to go with it. Also lower was Rite Aid (RAD), which slid 11% after the company reported earnings. INDEXES: Near midday, the Dow was up 43.02, or 0.19%, to 22,383.73, the Nasdaq was down 8.62, or 0.13%, to 6,444.64, and the S&P 500 was up 1.56, or 0.06%, to 2,508.60.

ABBV

AbbVie

$89.43

4.68 (5.52%)

AMGN

Amgen

$184.88

-0.72 (-0.39%)

BBRY

BlackBerry

$9.23

0.09 (0.98%)

CVX

Chevron

$117.51

0.06 (0.05%)

SPPI

Spectrum

$10.97

1.07 (10.81%)

ABT

Abbott

$53.81

1.6634 (3.19%)

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

RAD

Rite Aid

$2.03

-0.255 (-11.18%)

  • 28

    Sep

  • 28

    Sep

  • 18

    Oct

  • 08

    Nov

  • 09

    Nov

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

ABBV AbbVie
$89.43

4.68 (5.52%)

09/27/17
FBCO
09/27/17
NO CHANGE
Target $17
FBCO
Outperform
Coherus Biosciences price target lowered to $17 from $24 at Credit Suisse
Credit Suisse analyst Alethia Young lowered her price target for Coherus Biosciences (CHRS) to $17 from $24 as she is pushing her worldwide launch timeline assumption to 2022 from 2020 for the biosimilar Humira from AbbVie (ABBV). The analyst reiterates an Outperform rating on Coherus Biosciences shares.
09/28/17
JEFF
09/28/17
NO CHANGE
Target $107
JEFF
Buy
AbbVie Humira settlement increases visibility, says Jefferies
Jefferies analyst Jeffrey Holford said AbbVie's (ABBV) settlement of its patent fight with Amgen (AMGN) over Humira provides incremental reassurance that biosimilars are unlikely to launch in the U.S. before 2023. While there will still be "noise" on this issue given the many biosimilar developers, he recommends investors focus on AbbVie's pipeline, whose value should become more visible within the next year. Holford keeps a Buy rating and $107 price target on AbbVie shares.
09/25/17
09/25/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UAA) downgraded to Neutral from Buy at Guggenheim. 2. VF Corp. (VFC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Edward Yruma saying the company's "consistent" results are adequately reflected in the current valuation. 3. Quest Diagnostics (DGX) downgraded to Market Perform from Outperform at Raymond James with analyst Nicholas Jansen citing the preliminary 2018 Clinical Laboratory Fee Schedule, or CLFS, rates released Friday evening, which creates an overhang. 4. AbbVie (ABBV) downgraded to Neutral from Buy at UBS with analyst Marc Goodman saying that shares are up 40% year-to-date. 5. Albemarle (ALB) downgraded to Neutral from Outperform at Baird with analyst Ben Kallo saying he thinks near-term execution is largely priced into the stock and he believes the shares are fully valued at current levels. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/17
PIPR
09/28/17
NO CHANGE
Target $102
PIPR
Overweight
AbbVie settlement should shift debate on shares, says Piper Jaffray
AbbVie (ABBV) and Amgen's (AMGN) global resolution of all intellectual property-related litigation relating to Humira should further reinforce the validity of AbbVie's intellectual property beyond its recent inter partes review victories, Piper Jaffray analyst Richard Purkiss tells investors in a research note. The analyst raised his price target for AbbVie shares to $102 from $102 saying the settlement likely extends by five months his most recent assumption on the timing of U.S. biosimilar entry. Further, greater certainty on Humira biosimilar should shift the debate on AbbVie shares to the pipeline, Purkiss contends. He reiterates an Overweight rating on the name.
AMGN Amgen
$184.88

-0.72 (-0.39%)

09/21/17
UBSW
09/21/17
NO CHANGE
Target $500
UBSW
Buy
Regeneron price target lowered to $500 from $535 at UBS
UBS analyst Carter Gould lowered his price target on Regeneron (REGN) to $500 from $535 citing increased Dupixent competition after Amgen (AMGN) and AstraZeneca (AZN) reported data on their own asthma drug earlier this month and AbbVie (ABBV) reported results in an atopic dermatitis study. While he noted that definitive 12-month phase 3 data from these competitors is likely more than 20 months away, he also lowered his Dupixent peak sales estimate to $4.8B from $6.5B. He keeps a Buy rating on Regeneron shares, as he believes pipeline products including nesvacumab and REGN2810 offer a path to longer-term upside.
09/25/17
JEFF
09/25/17
NO CHANGE
Target $200
JEFF
Buy
Jefferies explains how Amgen can re-rate higher like AbbVie
Jefferies analyst Michael Yee believes the 2018-2020 consensus estimates for Amgen (AMGN) may be too low if Mylan's (MYL) biosimilar of Neulasta doesn't get approved next month. The Biosimilar User Fee Act date is October 9. Investors may become more confident in the durability of Amgen's franchise given that AbbVie (ABBV) defended Humira and re-rated to a higher valuation, Yee tells investors in a research note. The key issue keeping Amgen's price-to-earnings multiple below peers at 12 to 13 times over the past couple of years is investor fear of biosimilars primarily against Neulasta and Enbrel, Yee argues. He sees a failed approval for Mylan as setting the tone for a higher multiple like AbbVie. The analyst has a Buy rating on Amgen shares with a $200 price target.
BBRY BlackBerry
$9.23

0.09 (0.98%)

09/22/17
RBCM
09/22/17
NO CHANGE
Target $9.5
RBCM
Sector Perform
BlackBerry can use $1.6B of cash on acquisitions, says RBC Capital
RBC Capital analyst Paul Treiber says BlackBerry (BBRY) has $2.36B in cash after the $940M award from Qualcomm (QCOM). The company can use up to $1.6B of the cash on acquisitions, which may be accretive to earnings and the stock price, Treiber tells investors in a research note. He fells an acquisition of a company with organic growth above BlackBerry's targeted 10%-15% software growth "would be a tailwind to BlackBerry's organic growth." Treiber expects in-line Q2 results from BlackBerry on September 28 and keeps a Sector Perform rating on the shares.
09/22/17
BOFA
09/22/17
NO CHANGE
Target $8
BOFA
Underperform
BlackBerry valuation unattractive, says BofA/Merrill
BofA/Merrill analyst Daniel Bartus continues to view BlackBerry's valuation as unattractive saying the company has a long path to profitability, the Enterprise segment valuation is too high, QNX is low growth and at risk of share loss near-term, and Q1 software/services growth was due to a shift from handset related revenues. The analyst raised his price target on BlackBerry to $8 from 7.50 and maintained an Underperform rating on shares.
08/07/17
08/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. XPO Logistics (XPO) resumed with an Outperform at William Blair. 2. BlackBerry (BBRY) reinstated with a Sell at Goldman Sachs. 3. Brighthouse Financial (BHF) was initiated with a Sell at Citi, a Market Perform at Keefe Bruyette, FBR Capital, and Wells Fargo, a Sector Perform at RBC Capital, and a Neutral at Credit Suisse. 4. Zoetis (ZTS) reinstated with a Neutral at Goldman Sachs. 5. BeiGene (BGNE) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/11/17
ADAM
08/11/17
NO CHANGE
Target $10
ADAM
Hold
BlackBerry equipped to invest for growth, says Canaccord
Canaccord analyst T. Michael Walkley said Blackberry management gave an upbeat presentation at the firm's conference and explained how the company has completed its transformation into an enterprise software and services company. The analyst noted the company's strong balance sheet, including its cash balance, lead him to believe they have the capital to invest for growth by both hiring and through acquisition. Walkley maintained his Hold rating and $10 price target on Blackberry shares.
CVX Chevron
$117.51

0.06 (0.05%)

07/11/17
BERN
07/11/17
NO CHANGE
BERN
Oil price forecast cut at Bernstein
Bernstein analysts lowered their 2017 and 2018 oil price forecasts to $50 per barrel for both years. As reasons for the drop, the firm cited higher U.s. shale efficiency, their belief that elevated production levels will last longer than previously expected, and their belief that OPEC cuts will be insufficient to counter increased production by Libya, Iran and Nigeria. Publicly traded companies in the oil space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT).
08/07/17
EXAN
08/07/17
UPGRADE
Target $105
EXAN
Neutral
Chevron upgraded to Neutral from Underperform at Exane BNP Paribas
Exane BNP Paribas analyst Theepan Jothilingam upgraded Chevron to Neutral with a $105 price target,
07/17/17
WOLF
07/17/17
DOWNGRADE
WOLF
Peer Perform
Chevron downgraded to Peer Perform from Outperform at Wolfe Research
08/08/17
DBAB
08/08/17
NO CHANGE
DBAB
Deutsche views Pioneer Natural, peers as 'significantly oversold'
Deutsche Bank analyst Ryan Todd believes Pioneer Natural Resources (PXD) as well as the Permian Exploration & Production space are "significantly oversold" following Pioneer's Q2 results last week. The higher gas content of the production stream started an investor debate around the long-term risks to Permian production and resource value, Todd tells investors in a research note. He calls investor fears "wildly overblown" and is a buyer of the group, especially Pioneer Natural. The analyst has Buy ratings on the shares as well as Anadarko Petroleum (APC), ConocoPhillips (COP), Chevron (CVX) and Devon Energy (DVN).
SPPI Spectrum
$10.97

1.07 (10.81%)

02/10/17
JEFF
02/10/17
UPGRADE
Target $7.5
JEFF
Buy
Spectrum assumed with a Buy from Hold at Jefferies
Jefferies analyst Matthew Andrews upgraded Spectrum Pharmaceuticals to Buy after assuming coverage of the name. The stock is undervalued based on Rolontis' long-term promise in chemotherapy-induced neutropenia, Andrews tells investors in a research note. The analyst sees 50%-plus share upside on expectations that Rolontis is lower risk and should gain meaningful market share from Neulasta. He has a $7.50 price target for Spectrum.
09/25/17
JEFF
09/25/17
NO CHANGE
Target $13
JEFF
Buy
Spectrum price target raised to $13 from $9 at Jefferies
Jefferies analyst Matthew Andrews raised his price target for Spectrum Pharmaceuticals to $13 ahead of initial Phase II data at the World Conference on Lung Cancer. The analyst views poziotinib as an "under the radar" non-small cell lung cancer drug. He sees exon 20 as a potential $1B U.S. market for poziotinib. If the overall response rate in Phase II around 25%, the drug could qualify for FDA Breakthrough Designation and reach the market by 2020, which could drive "meaningful" upside to Spectrum shares, Andrews tells investors in a research note. He keeps a Buy rating on the name.
08/16/17
HCWC
08/16/17
INITIATION
Target $14
HCWC
Buy
Spectrum assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Edward White assumed coverage of Spectrum Pharmaceuticals with a Buy rating and $14 price target. The analyst has confidence in the company's pipeline, which he believe holds two potential blockbusters in Rolontis and poziotinib.
09/28/17
JEFF
09/28/17
NO CHANGE
Target $13
JEFF
Buy
Spectrum data early but encouraging, says Jefferies
Jefferies analyst Matthew Andrews believes abstracts for the World Conference on Lung Cancer show "very encouraging efficacy" for Spectrum Pharmaceuticals' poziotinib. In a research note titled "Poziotinib WCLC Data Don't Disappoint...Can't Beat 100% ORR," Andrews says he continues to see "meaningful upside" in Spectrum shares through the end of 2017. The two partial responses complement the PR observed in a HER2 exon 20 patient in a compassionate use study, the analyst notes. He keeps a Buy rating on Spectrum with a $13 price target. The stock in premarket trading is up 3.65% to $11.37.
ABT Abbott
$53.81

1.6634 (3.19%)

09/28/17
WBLR
09/28/17
NO CHANGE
WBLR
Outperform
William Blair sees Dexcom retaining advantage over Abbott
William Blair analyst Margaret Kaczor says that while she didn't think Abbott's (ABT) Libre Flash Glucose Monitoring device would receive a dosing claim given the product's "inferior accuracy," Libre still lacks DexCom's (DXCM) alerts and alarms that proactively protect the patient from glycemic excursions. Libre's dosing may shift the competitive dynamic "modestly in Abbott's favor versus Street expectations," but more importantly, its approval should be market expansive as it creates a new type of glucose monitoring category in the United States, Kaczor tells investors in a research note. The analyst believes DexCom will retain a "material technological and brand advantage." Further, the company has a "rich product pipeline" including its own 10-day G6 sensor that is nearing approval, the analyst adds. She keeps an Outperform rating on Dexcom. Kaczor thinks the stock, at last night's price between $55 and $56, adequately prices in risk of share loss in the category. Dexcom in premarket trading is down 29% to $47.93.
09/28/17
NORL
09/28/17
DOWNGRADE
Target $60
NORL
Market Perform
Dexcom downgraded to Market Perform from Outperform at Northland
Northland analyst Suraj Kalia downgraded Dexom (DXCM) to Market Perform and cut its price target to $60 from $85 following the surprise PMA approval of Abbott's (ABT) Libre flash glucose monitor for a 10-day use. The analyst said Libre received a concomitant nonadjunctive to fingersticks label, which came as a surprise, and removes a key competitive advantage for Dexcom.
09/28/17
COWN
09/28/17
NO CHANGE
Target $64
COWN
Outperform
Dexcom price target lowered to $64 from $90 at Cowen
Cowen analyst Doug Schenkel lowered his price target on Dexcom (DXCM) to $64 from $90 and lowered his estimates to reflect the approval of the Abbott (ABT) Libre, with a dosing claim, at least a year earlier than expected. The claim is important because it is a precursor for CMS reimbursement, said Schenkel. He keeps his Outperform rating on Dexcom pending additional details and based on the magnitude of its glucose monitoring opportunity.
09/28/17
BMOC
09/28/17
NO CHANGE
BMOC
Dexcom price target lowered to $62 from $90 at BMO Capital
BMO Capital analyst JoanneK.Wuensch lowered her price target on Dexcom (DXCM) after Abbott (ABT) received FDA approval for a competing product. The analyst says the approval was unexpected, but she says that Dexcom's product is "materially superior." She thinks that the company's "long-term growth story remains intact," and she keeps an Outperform rating on the shares.
DXCM Dexcom
$67.47

-0.45 (-0.66%)

09/28/17
09/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dexcom (DXCM) was downgraded to Market Perform from Outperform at Raymond James and Northland and to Neutral from Overweight at JPMorgan. 2. Pier 1 Imports (PIR) downgraded to Hold from Buy at Loop Capital with analyst Anthony Chukumba saying near-term visibility will remain low as investors await management's new turnaround plan and the retailer's profitability will remain under pressure due to increased competition. 3. trivago (TRVG) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Brian Nowak saying he believes online travel agencies Priceline (PCLN) and Expedia (EXPE) are reducing their spending with the company, which he sees making comparables tough until the second half of next year. 4. AutoNation (AN) downgraded to Neutral from Positive at Susquehanna. 5. Bunge (BG) and Archer Daniels (ADM) were downgraded to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RAD Rite Aid
$2.03

-0.255 (-11.18%)

09/11/17
LOOP
09/11/17
INITIATION
Target $2.5
LOOP
Hold
Rite Aid initiated with a Hold at Loop Capital
Loop Capital analyst Andrew Wolf started Rite Aid (RAD) with a Hold rating and $2.50 price target, stating that he views the company's re-worked store sale to Walgreens (WBA) as a "re-launch of Rite Aid's turnaround efforts" and believes it lacks intermediate term earnings visibility.
09/19/17
RBCM
09/19/17
INITIATION
RBCM
Sector Perform
Rite Aid initiated with a Sector Perform at RBC Capital
RBC Capital analyst George Hill started coverage of Rite Aid with a $2.50 price target and a Sector Perform rating.
08/23/17
UBSW
08/23/17
NO CHANGE
Target $96
UBSW
Buy
Walgreens Boots Alliance should see upside from new Rite Aid deal, says UBS
UBS analyst Michael Cherny said his review of the new Walgreens Boots Alliance (WBA) deal with Rite Aid (RAD) would provide immediate accretion from synergy opportunities if the deal is approved. He believes it can provide meaningful upside to earnings as well as remove the lack of clarity on capital deployment-driven earnings contribution. Thus, he sees the shares as having a positive risk/reward skew. Cherny reiterated his Buy rating and lowered his price target to $96 from $97 on Walgreens shares.
09/12/17
09/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with an Outperform at Macquarie. 2. Bunge (BG) initiated with a Neutral at Baird. 3. Rite Aid (RAD) initiated with a Hold at Loop Capital. 4. Nike (NKE) was initiated with an Outperform at Bernstein, while Under Armour (UA) was initiated with an Underperform. 5. Houlihan Lokey (HLI) initiated with an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

20:45
10/16/17
10/16
20:45
10/16/17
20:45
General news
Breaking General news story  »

Minneapolis Federal…

20:25
10/16/17
10/16
20:25
10/16/17
20:25
Conference/Events
Federal Reserve Bank of Minneapolis participates in a dinner meeting »

Minneapolis Federal…

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

, UNH

UnitedHealth

$193.20

0.68 (0.35%)

20:25
10/16/17
10/16
20:25
10/16/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$136.12

-0.31 (-0.23%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

GS

Goldman Sachs

$242.41

3.88 (1.63%)

MS

Morgan Stanley

$48.94

0.64 (1.33%)

CSX

CSX

$52.84

0.01 (0.02%)

PGR

Progressive

$48.98

0.31 (0.64%)

CMA

Comerica

$75.34

-0.21 (-0.28%)

GWW

Grainger

$182.36

1.31 (0.72%)

HOG

Harley-Davidson

$46.57

-0.05 (-0.11%)

SNV

Synovus

$46.65

0.01 (0.02%)

TTS

Tile Shop

$8.45

0.1 (1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 15

    Nov

  • 24

    Jan

MSBI

Midland States

$33.03

-0.07 (-0.21%)

19:02
10/16/17
10/16
19:02
10/16/17
19:02
Hot Stocks
Midland States to acquire Alpine Bancorporation in roughly $181M deal »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

MYL

Mylan

$38.18

0.23 (0.61%)

, AGN

Allergan

$198.41

-7.11 (-3.46%)

18:46
10/16/17
10/16
18:46
10/16/17
18:46
Hot Stocks
Mylan CEO: 'Pleased' with court ruling on Allergan's Restasis patents »

Mylan (MYL) announced…

MYL

Mylan

$38.18

0.23 (0.61%)

AGN

Allergan

$198.41

-7.11 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

  • 03

    Dec

NFLX

Netflix

$202.68

3.19 (1.60%)

18:44
10/16/17
10/16
18:44
10/16/17
18:44
Hot Stocks
Netflix says seeing steady growth, great success for streaming »

Says still has bias…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

PCG

PG&E

$53.43

-4.29 (-7.43%)

18:42
10/16/17
10/16
18:42
10/16/17
18:42
Hot Stocks
PG&E sees restoring service to all electric customers in CA affected by fires »

PG&E said that more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 05

    Nov

  • 05

    Nov

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

18:29
10/16/17
10/16
18:29
10/16/17
18:29
Hot Stocks
CytRx granted listing extension pending results of stockholder vote »

CytRx 's request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

EADSY

Airbus

$22.75

-0.07 (-0.31%)

, BDRBF

Bombardier

$1.88

0.03 (1.62%)

18:27
10/16/17
10/16
18:27
10/16/17
18:27
Hot Stocks
Airbus and Bombardier announce C Series partnership »

Airbus (EADSY) and…

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BDRBF

Bombardier

$1.88

0.03 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

18:16
10/16/17
10/16
18:16
10/16/17
18:16
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

PG

Procter & Gamble

$93.14

0.1 (0.11%)

18:15
10/16/17
10/16
18:15
10/16/17
18:15
Hot Stocks
Trian: P&G board election results 'too close to call' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

18:14
10/16/17
10/16
18:14
10/16/17
18:14
Periodicals
NJ leaders offer up to $7B in tax incentives to lure Amazon to Newark, WSJ says »

New Jersey Governor Chris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

18:09
10/16/17
10/16
18:09
10/16/17
18:09
Periodicals
Bombardier in talks with Airbus over CSeries jet unit JV, WSJ reports »

Bombardier (BDRBF) is in…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.